Tuoxin Pharmaceutical Group Co.,Ltd. (SHE:301089)

China · Delayed Price · Currency is CNY

21.92

+0.22 (1.01%)

At close: Oct 23, 2026

Market Cap	2.77B -33.1%
Revenue (ttm)	407.75M +6.0%
Net Income	-79.34M
EPS	-0.64
Shares Out	126.54M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,762,100
Open	21.40
Previous Close	21.70
Day's Range	20.36 - 21.98
52-Week Range	19.33 - 36.34
Beta	-0.61
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 27, 2026

About SHE:301089

Tuoxin Pharmaceutical Group Co.,Ltd. engages in the research and development, production and sales of nucleoside (acid) APIs and pharmaceutical intermediates in China. It offers nucleoside (acid) products, such as pyrimidine series, purine series, and nucleotide series; nucleoside series, including citicoline sodium, ribavirin, inosine, acyclovir, cytosine, 5-fluorocytosine, cytidine, uridine; and other APIs and pharmaceutical intermediates covering antiviral, anti-tumor, and nervous system. The company was founded in 2001 and is based in Xinxi... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 2001

Employees 1,543

Stock Exchange Shenzhen Stock Exchange

Ticker Symbol 301089

Full Company Profile

Financial Performance

In 2025, SHE:301089's revenue was 378.34 million, a decrease of -10.28% compared to the previous year's 421.69 million. Losses were -69.66 million, 250.3% more than in 2024.

Financial Statements